StockDrifts LogoStockDrifts

GL Pharmtech 204840

Company
지엘팜텍GL Pharmtech
Insiders
1
Buys
0
Total Value
₩13M ($9K)
Avg Return
+19.69%
Last Filing
2024-03-07

GL Pharmtech (204840) has 0 disclosed insider purchases and 1 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩13M ($9K) in reported transaction value. The earliest filing StockDrifts holds for GL Pharmtech is dated 2024-03-06; the most recent is 2024-03-07. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +19.69%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-08-01BUY신규선임
박상태
Park Sang-tae
Gyeongsan Factory Manager5.2K₩814+0.0%₩4M ($3K)
2024-03-07BUY제3자배정유상증자
더블유사이언스
W Science
-13.8M₩1,417-19.7%₩19.6B ($13.6M)
2024-03-07SELLMarket Sell
이상제일호사모투자
Lee Sangjeilho Private Investment
--9.2K₩1,417+19.7%₩13M ($9K)
2024-03-06SELL장외매도
왕훈식
Wang Hoon-sik
CEO-915.7K₩1,407+19.1%₩1.3B ($895K)
2024-03-06BUY장외매수
더블유사이언스
W Science
-6.3M₩1,407-19.1%₩8.9B ($6.2M)
2024-03-06SELL장외매도
이상제일호사모투자
Lee Sangjeilho Private Investment
--4.9M₩1,407+19.1%₩6.9B ($4.8M)

Frequently asked questions

Who has been buying GL Pharmtech stock?
1 distinct insiders have filed 0 disclosed insider purchases in GL Pharmtech (204840), most recently on 2024-03-07. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does GL Pharmtech have?
GL Pharmtech has 0 buy-side and 1 sell-side disclosures on record, covering ₩13M ($9K) in total reported value, spanning 2024-03-06 to 2024-03-07.
Where does StockDrifts get GL Pharmtech insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for GL Pharmtech. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.